Biotech RadarJobs updated

COMPANY

Transcend Therapeutics

transcendtherapeutics.com ↗

Clinical Phase 3

Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Transcend Therapeutics is developing TSND-201 (methylone) for post-traumatic stress disorder (PTSD), major depressive disorder (MDD) and other central nervous system (CNS) indications. From company website Source · checked 2026-10-19

Sources for this description (2)
  • Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases.
    • “Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases.” https://transcendtherapeutics.com/about-us/ (2026-10-19)
  • Transcend Therapeutics is developing TSND-201 (methylone) for post-traumatic stress disorder (PTSD), major depressive disorder (MDD) and other central nervous system (CNS) indications.
    • “We are developing TSND-201 (methylone) as a rapid-acting and durable treatment for Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other Central Nervous System (CNS) indications.” https://transcendtherapeutics.com/about-us/ (2026-10-19)

Disease: post-traumatic stress disorder major depressive disorder

Product: TSND-201

Keywords: neuropsychiatric Post Traumatic Stress Disorder Methylone

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD source ↗
  2. Trial start Phase 3: An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD source ↗
  3. Trial start Phase 3: An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) source ↗
  4. Trial start Phase 2: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD source ↗
  5. Trial start Phase 1: A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects source ↗
  6. Trial start Phase 2: An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD source ↗
  7. Trial start Phase 1/Phase 2: A Study to Assess the Use of Methylone in the Treatment of PTSD source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT07836647An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSDPhase 3Recruiting2026-092028-02 (estimated)
NCT07456696An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)Phase 3RecruitingApr 2, 20262027-12 (estimated)
NCT07670702An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSDPhase 3Enrolling by invitationJun 22, 20262028-12 (estimated)
NCT05741710A Study to Assess the Use of Methylone in the Treatment of PTSDPhase 1/Phase 2CompletedMar 1, 2023Feb 19, 2025 (actual)
NCT06237426An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSDPhase 2CompletedMar 6, 2024Oct 6, 2025 (actual)
NCT06215261An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSDPhase 2CompletedApr 4, 2024Sep 23, 2025 (actual)
NCT06303648A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy SubjectsPhase 1CompletedMar 20, 2024Jul 13, 2025 (actual)
Feedback